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Background: Chronic hepatitis C affects approximately 170 million people worldwide, and thus being one of the
main causes of chronic liver disease. About 20% of patients with chronic hepatitis C will develop cirrhosis over 20
years, and present an increased risk of developing hepatic complications. Sustained virological response (SVR) is
associated with a better prognosis compared to untreated patients and treatment failures.
The objective of this analysis was to compare treatment costs and outcomes of pegylated interferon-alfa-2a versus
pegylated interferon-alfa-2b, both associated with ribavirin, in the therapeutic scheme of 24 weeks and 48 week for
hepatitis C genotypes 2/3 and genotype 1, respectively, under the Brazilian Public Health System (SUS) scenario.
Methods: To project disease progression, a Markov model was built based on clinical stages of chronic disease. A
Delphi panel was conducted to evaluate medical resources related to each stage, followed by costing of related
materials, services, procedures and pharmaceutical products. The evaluation was made from a public payer
perspective. The source used for costing was government reimbursement procedures list (SAI/SIH–SUS). Drug
acquisition costs were obtained from the Brazilian Official Gazette and “Banco de Preços em Saúde” (government
official source). It was assumed a mean patient weight of 70 kg. Costs were reported in 2011 Brazilian Reais
(US$1 ≈ $Brz1.80). A systematic review followed by a meta-analysis of the 7 identified randomized controlled trials
(RCTs) which compared pegylated interferons, was conducted for obtaining relative efficacy of both drugs: for
genotype 2/3, mean rate of SVR was 79.2% for peginterferon-alfa-2a and 73.8% for peginterferon-alfa-2b. For
genotype 1, SVR mean rate was 42.09% versus 33.44% (peginterferon-alfa-2a and peginterferon-alfa-2b respectively).
Time horizon considered was lifetime. Discount rate for costs and outcomes was 5%, according to Brazilian
guidelines for Health Technology Assessment (HTA).
Results: Analysis showed that peginterferon-alfa-2a is a dominant therapy compared to peginterferon-alfa-2b for
genotype 1 ($Brz 4,345 savings and 0.10 LY/0.25 QALY gains) as well for genotype 2/3 ($Brz 8,001 savings and 0.16
LY/0.39 QALY gains). Projections indicated that for each 1000 patients treated with peginterferon-alfa-2a instead of
peginterferon-alfa-2b, the amount of resources saved would be of $Brz 4.3 million for genotypes 2/3 and up to $Brz
8 million for genotype 1.
Conclusion: These findings suggest that treatment with peginterferon-alfa-2a is more effective and less costly
when compared to peginterferon-alfa-2b under SUS perspective in Brazil.
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Hepatitis C virus (HCV) identification is relatively recent
(1989) [1] and many efforts were made in the last years
to optimize its pharmacological treatment and disease
detection rates.
HCV infection becomes chronic in approximately 75%–
85% of cases, significantly raising healthcare costs, espe-
cially those resulting from hospital bills. According to
Wong et al., infection with hepatitis C virus is the leading
cause in approximately 30% of liver transplantation, 40%
of cases of decompensated cirrhosis and 60% of hepato-
cellular carcinoma [2]. Sustained virological response
(SVR) in chronic hepatitis C is associated with better
prognosis, since observed reduction in clinical events,
mainly liver failure is observed when SVR is achieved [3].
In 2010, Brazilian Ministry of Health published infor-
mation on anti-HCV (antibody to the hepatitis C virus,
its presence indicates an active or chronic hepatitis C in-
fection) prevalence in Brazilian capital cities; estimated
anti-HCV prevalence was 2.1% in North Region, 0.7% in
Northeast Region, 1.3% in Central-West Region, 1.3% in
Southeast Region and 1.2% in South Region [4]. A total
of 60,908 cases of hepatitis C were confirmed and regis-
tered in Brazil from 1999 to 2009 according to 2010
Viral Hepatitis Epidemiological Bulletin [5].
According to Brazilian Ministry of Health, in 2011,
expenses with Hepatitis C achieved around $Brz 17.7
million [6]. Moreover, disease’s chronic nature and its
successive stages, such as cirrhosis, hepatocellular car-
cinoma or liver transplantation and negative issues pro-
duced by disease, such as absenteeism, early retirement,
loss of productivity, aggravate social and economic bur-
den related to HCV infection. In this scenario, the adop-
tion of cost-effective strategies would beneficiate health
policy makers, society and patients.
In the Public Healthcare System of Brazil (SUS),
according to the therapeutic guidelines and clinical pro-
tocols for hepatitis C [7], patients with genotype 1 aged
from 18 to 70 years old, with platelet counts > 90,000/
mm3 (non cirrhotic) or > 75,000/mm3 (cirrhotic) after
qualitative PCR (Polymerase Chain Reaction), should be
treated with pegylated interferon alfa-2a or 2b weekly
and ribavirin 15 mg/kg daily for 48-72-week treatment
period. Patients with genotypes 2 or 3, in the absence of
low SVR predictors – METAVIR score ≥ F3 or clinical
manifestations of cirrhotic fibrosis or viral load >
600,000 UI/mL –, should be treated with conventional
interferon alfa-2a or 2b, 3 times a week and ribavirin 15
mg/kg daily for 24-week treatment period; in the pres-
ence of low SVR predictors, patients should be treated
with pegylated interferon alfa-2a or 2b weekly and riba-
virin 15 mg/kg daily for 24-48-week treatment period.
The guideline doesn’t mention any differences between
efficacies of both pegylated interferons. However,literature has been discussing the clinical superiority of
one of them, with the tendency to peginterferon-alfa-2a
[8-13]. Economic assessment comparing peginterferon-
alfa-2a and peginterferon-alfa-2b in Chronic Hepatitis C
indicates that the first one was considered cost-effective
or even dominant in several countries like: USA, UK,
Spain, Poland and Mexico [14-20].
The objective of this analysis was to assess the
cost-effectiveness ratio of peginterferon-alfa-2a versus
peginterferon-alfa-2b both plus ribavirin (RBV), in a
24-week therapeutic schedule in the treatment of pa-
tients with chronic hepatitis C, genotypes 2 and 3 or
48-week schedule for genotype 1, from the perspective
of the Public Health Care System in Brazil. In order to
obtain efficacy data for the analysis, our aim was also to
conduct a systematic review of RCTs and perform a
meta-analysis of the results.
Methods
We used a Markov model to simulate the progression of
chronic hepatitis C in a hypothetical cohort of patients
with initial age of 45 years old presenting antibodies
against hepatitis C virus (anti-HCV) or HCV RNA posi-
tivity in individuals known to be previously negative.
The model predicted long-term clinical benefits (Life
Years - LYs and Quality Adjusted Life Years - QALYs)
and associated costs with each intervention, providing
the incremental cost-effectiveness ratio (ICER) of
peginterferon-alfa-2a versus peginterferon-alfa-2b, both
associated with ribavirin. A one-way sensitivity analysis
was also conducted in order to assess the impact of un-
certainty on the cost-effectiveness ratio.
Model description
A Markov model was used as it allows representing the
relevant stages of the natural history of the disease over
time, as well as estimates for probability of progression
between the several health states related to the chronic
infection with hepatitis C virus.
Each scenario was comprised by 7 mutually excluding
clinical stages, each of which was defined by a patient’s
clinical condition: sustained virological response, chronic
hepatitis C, compensated cirrhosis, decompensated cir-
rhosis, hepatocellular carcinoma, liver transplantation
and death, enabling the comparison of final outcomes
between therapeutic alternatives.
Associated with each of the clinical stages, quality-of-life
values and costs were attributed. Costs associated to
Markov stages intended to reflect local medical practice,
and resource utilization was determined by a Delphi
panel. The panel included prescribing professionals from
the public healthcare system. All costs and outcomes were
discounted at a 5% rate, according to the Brazilian Guide-
lines for Health Technology Assessment (HTA) [21].
Figure 1 Diagram for patients chronically infected with hepatitis C virus: Diagrams of transition for treatment of chronic infection with
hepatitis C virus in mutually excluding stages.
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Following, we present diagrams of transition for treatment
of chronic infection with hepatitis C virus in mutually
excluding stages (Figure 1). Consequently, each patient
will correspond to one of the stages at a given time.
The model was similar to others described in literature
[22-24]. Patients start at the chronic hepatitis C stage,
undergo a 24-weeks treatment with peginterferon-
alfa-2a plus ribavirin or peginterferon-alfa-2b plus ribavi-
rin if genotypes 2/3 and 48-weeks treatment with the
same drugs if genotype 1. No extension on treatment
schedule was considered.
The time horizon of the analysis accounted for pa-
tient’s lifetime and was divided into equal increments of
time, known as Markov cycles. Each cycle comprises one
year and defines possible pathway for each patient in theTable 1 Transition probabilities employed in the model
Health status Transition Probability
(annual)
From To Rate























Liver transplant Death (1st year)
[24,29,32-34]
0.210
Liver transplant Death (> 1 year)
[24,29-32]
0.057model based on the natural history of the infection with
hepatitis C virus. The probability for a patient to migrate
between two stages during a cycle is called probability of
transition between stages. Following 24 or 48 weeks of
treatment, patients may show positive response to treat-
ment or recurrence every year.
After the treatment cycle, patients can either respond
to treatment, which means moving to sustained viro-
logical response stage, remain at the chronic stage or
progress to compensated cirrhosis. When at the com-
pensated cirrhosis, patients can remain on the stage or
progress either to hepatocellular carcinoma or decom-
pensated cirrhosis. Patients who develop decompensated
cirrhosis could remain on the stage, develop hepatocel-
lular carcinoma, receive a liver transplantation or have
an increased risk disease-related mortality. Finally, pa-
tients at the liver transplantation stage or hepatocellular
carcinoma can remain on the stage or die.
Transition probabilities
We reviewed clinical and pharmacoeconomic literature
aiming to identify studies reporting probability of clinical
events which were relevant for the model. These data
are presented in the Table 1 [25-34].Table 2 Medical costs for treating several stages of
chronic infection with hepatitis C virus
Cost item Cost data
Cost / year / patient
Chronic hepatitis C $Brz 586
Compensated cirrhosis $Brz 852
Decompensated cirrhosis $Brz 21,716
Hepatocellular carcinoma $Brz 12,526
Liver transplant, 1st year $Brz 63,013
Liver transplant, subsequent year $Brz 7,777
Notes: Costs based on SAI/SIH–SUS for procedures and Brazilian Official
Gazette or “Banco de Preços em Saúde” for drugs.
Table 3 Weekly cost for both pegylated interferons
Peginterferon-alfa-2a Peginterferon-alfa-2b
Drugs cost 180 μg /week –
$Brz 269.09




$Brz 16.72 $Brz 16.72
Weekly cost $Brz 285.82 $Brz 398.20
Table 5 Study inclusion criteria
Criteria Definition
Population Patients infected with hepatitis C virus (HCV)
not co-infected with HIV.
Intervention Pegylated interferon alfa – 2a plus ribavirin (RBV)
Comparator Pegylated interferon alfa – 2b plus ribavirin
Outcome Sustained Virological Response (SVR)
Study type Randomized controlled trials
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parameters for each of the stages of chronic hepatitis
C, compensated cirrhosis, decompensated cirrhosis,
hepatocellular carcinoma, liver transplantation, post-
transplantation and death. All patients had their risk of
death adjusted by the Brazilian Agency for Geography
and Statistics (IBGE) life table, which provides mortality
rates for the Brazilian population [35].
Quality of life
Relevant data concerning quality-of-life values (utilities)
were extracted from the international literature, due to
the lack of local data [24,29,36]. The utilities weights
assigned for each stage were: 0.90 for sustained viro-
logical response, 0.82 for chronic hepatitis C, 0.78 for
compensated cirrhosis, 0.65 for decompensated cirrho-
sis, 0.25 for hepatocellular carcinoma, 0.5 for liver trans-
plant at the 1st year, 0.7 for the subsequent years after
liver transplant and finally 0 for death.
Cost data
This study was performed using a public payer’s. Annual
medical resources related to each clinical stage of
chronic hepatitis C were collected through a Delphi
panel, which included experts in infectious diseases and
hepatology with 10 to 24-year experience in medical
practice. Source used for costing was government reim-
bursement procedures list (SAI/SIH–SUS) [37]. The ag-
gregated annual costs of managing each clinical stage
are shown in Table 2.
Since in Brazil peginterferon-alfa drugs are acquired in
a centralized purchasing process, their acquisition costs
were obtained from purchase invoices published in the
Brazilian Official Gazette [38-40]. Ribavirin acquisitionTable 4 Specific search strategy in databases
Search Database
1 Medline Exp hepatitis C.mp. and exp peginterferon a
2 Pubmed Exp hepatitis C.mp. and exp peginterferon a
3 Embase Exp hepatitis C.mp. and exp peginte
4 Cochrane Exp hepatitis C.mp. and exp peginterferon a
5 LILACS Exp hepatitis C.m
6 Hand search Internet searches and targeted sea
Notes: exp, explode—a search term that automatically includes closely related inde
subject heading.cost was taken from “Banco de Preços em Saúde” (BPS),
the government official source. Peginterferon-alfa 2a is
given at a dosage of 180 μg per week irrespectively of
patient weight and has only one presentation. However,
for peginterferon-alfa 2b, dosage is based on patient’s
weight (1.5 μg/kg/week) and has three distinct forms of
presentation with different prices per μg. As specified in
the peginterferon-alfa 2b SPC (summary of product
characteristics), we have considered that unused portion
of drug was wasted. Therefore, it was assumed a mean
patient weight of 70 kg (which means 105 μg of
peginterferon-alfa 2b) and the weighted average per μg
available at BPS was used. For ribavirin, recommended
dosage is 15 mg/kg/day. Costs were reported in 2011
Brazilian Reais (US$1 ≈ $Brz1.80) (Table 3).
Efficacy data
Efficacy data for pegylated interferons, both combined
with ribavirin, used in this cost-effectiveness study were
derived from a meta-analysis conducted in order to as-
sess relative treatment efficacy of peginterferon-alfa-2a
compared to peginterferon-alfa-2b both plus ribavirin.
Before carrying out the meta-analysis, a systematic re-
view of literature was performed.
An extensive search through main medical informa-
tion databases (MEDLINE, Cochrane Library, Embase
and Lilacs) and specialized websites was conducted on
the second trimester of 2010. We aim to identify RCTs
which evaluated treatment efficacy of peginterferon-
alfa-2a versus peginterferon-alfa-2b both plus ribavirin
for HCV treatment in patients not co-infected with HIV
(Table 4).Search Terms Results
lfa 2a.mp. and exp peginterferon alfa 2b.mp. NOT HIV[Title] 475
lfa 2a.mp. and exp peginterferon alfa 2b.mp. NOT HIV[Title] 402
rferon alfa 2a.mp. and exp peginterferon alfa 2b.mp. 222
lfa 2a.mp. and exp peginterferon alfa 2b.mp. NOT HIV[Title] 42
p. and exp peginterferon.mp. 12
rches in specialist liver websites and associations 4
xing terms; mp, multiple posting—term appears in title, abstract, or
Figure 2 Study selection flow chart: Seven papers out of 623 found (databases citation without duplicates plus manual searches)
which met our inclusion criteria were included in meta-analysis.
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screened and potentially relevant references were selected
by two independent reviewers. Abstract and full text of
the potential articles were also analyzed and the selection
of studies was made. Included studies were those which
evaluate treatment efficacy of peginterferon alfa-2a versus
peginterferon alfa-2b both plus ribavirin for hepatitis C
treatment in naïve patients or nonresponders to other
therapies not co-infected with HIV (Table 5).
To summarize all information gathered in our system-
atic review a meta-analysis was performed and according
to heterogeneity test, a fixed or a random-effect model
was considered.Figure 3 Forest Plot of studies comparing the effect of treatment wit
for genotypes 2/3: Peginterferon-alfa-2a showed higher SVR as comp
1.01 – 1.22, assuming a fixed-effect model).Sensitivity analysis
In order to assess the uncertainty of the results, a
one-way sensitivity analysis was performed. The pa-
rameters peginterferon-alfa-2a cost, peginterferon-
alfa-2b cost, state-transition probabilities; medical
costs and utility values were varied over the range of
15% (up and down); patient weight was varied from
50 to 90 kg; SVR was varied according to lower and
upper limit values obtained from meta-analysis and
starting age was varied from 40 to 50 years old. Sen-
sitivity analysis within same conditions was conducted
for cost-effectiveness analysis of genotype 1 and geno-
type 2/3.h peginterferon-alfa-2a vs standard-dose peginterferon-alfa-2b
ared to peginterferon-alfa-2b: 79.2% vs 73.8% (RR = 1.11, IC 95%
Figure 4 Forest Plot of studies comparing the effect of treatment with peginterferon-alfa-2a vs standard-dose peginterferon-alfa-2b
for genotype 1: Peginterferon-alfa-2a showed higher SVR as compared to standard dose of peginterferon-alfa-2b as well: 42.09%
versus 33.44% (RR = 1.10, IC 95% 1.01 – 1.20, assuming a fixed-effect framework).
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Meta-analysis
We identified seven papers out of 623 found (databases
citation without duplicates plus manual searches) which
met our inclusion criteria described above: 1) Ascione,
2009 [41] 2) Rumi, 2009 [42] 3) McHutchison, 2009 [43]
4) Yenice, 2006b [44] 5) Scotto, 2008 [45] 6) Berak, 2007
[46] and 7) Kolakowska, 2008 [47]. Not all papers evalu-
ated all patients’ genotypes, therefore, for genotype 2/3,
four papers were included in the meta-analysis and for
genotype 1, six papers were evaluated. All studies were
prospective randomized controlled trials (Figure 2).
For genotypes 2/3 peginterferon-alfa-2a showed higher
SVR as compared to peginterferon-alfa-2b: 79.2% versus
73.8% (RR = 1.11, IC 95% 1.01 – 1.22, assuming a fixed-
effect model) (Figure 3); for genotype 1 chronic HCV in-
fection patients, peginterferon-alfa-2a showed higher
SVR as compared to standard dose of peginterferon-
alfa-2b as well: 42.09% versus 33.44% (RR = 1.10, IC 95%
1.01 – 1.20, assuming a fixed-effect framework)
(Figure 4). These findings suggest that peginterferon-
alfa-2a is associated with a higher clinical response than
peginterferon-alfa-2b.
It is important to mention that only standard-dose
peginterferon-alfa-2b data were included in the meta-
analysis. Therefore, the effect of the low-dose: 1.0 μg/kgTable 6 Comparative chart of clinical and economic




Total costs LY1 QALY2 Result
Peginterferon-
alfa-2a + ribavirin




$Brz 17,465 15.11 14.32
Notes: 1LYs – Life years; 2QALYs – Quality Adjusted Life Years.of peginterferon-alfa-2b, analyzed in McHutchison [43],
2009 was excluded from the analysis in order to avoid a
possible negative impact over the results.
On the other hand, including peginterferon-alfa-2b
lower dose appear not to influence the results. A re-
cently published meta-analysis [8] (Awad, 2010) that did
not exclude the effects of low-dose treatment showed
similar results of efficacy of peginterferon-alfa-2a vs
peginterferon-alfa-2b presented in this study. For geno-
type 1, peginterferon-alfa-2a showed higher sustained
virological response when compared to peginterferon-
alfa-2b: 42.1% versus 33.3% (RR = 1.11, IC 95% 1.02 –
1.20, assuming a fixed-effect model).
Cost-effectiveness analysis
Our model predicted the costs and outcomes of each al-
ternative by combining the treatment expenses with the
costs related to each future stage of the disease
progression.
Genotypes 2/3
Overall cost for treatment with peginterferon-alfa-2a
was $Brz 13,120, while for peginterferon-alfa-2b, total
cost was $Brz 17,465. Treatment with peginterferon-
alfa-2a resulted in 15.21 LYs and 14.57 QALYs, while
treatment with peginterferon-alfa-2b resulted in 15.11Table 7 Comparative chart of clinical and economic













$Brz 39,186 14.35 12.50
Notes: 1LYs – Life years; 2QALYs – Quality Adjusted Life Years.
Table 8 One-way sensitivity analysis results for genotype 2/3 comparing peginterferon-alfa-2a to peginterferon-alfa-2b













Utility values1 -$Brz 4345 0,10 0,34 -$Brz 4345 0,10 0,17 Dominant
Medical costs1 -$Brz 4098 0,10 0,26 -$Brz 4592 0,10 0,26 Dominant
State-transition probabilities1 -$Brz 4250 0,08 0,22 -$Brz 4411 0,13 0,27 Dominant
Peginterferon-alfa-2a acquisition
cost1
-$Brz 5314 0,10 0,26 -$Brz 3376 0,10 0,26 Dominant
Peginterferon-alfa-2b acquisition
cost1
-$Brz 2972 0,10 0,26 -$Brz 5718 0,10 0,26 Dominant
Patient weight2 -$Brz 1729 0,10 0,26 -$Brz 6961 0,10 0,26 Dominant
SVR3 -$Brz 3576 0,05 0,14 -$Brz 5114 0,15 0,38 Dominant
Starting age4 -$Brz 4459 0,13 0,29 -$Brz 4927 0,09 0,22 Dominant
Notes: 1Parameters were varied over the range of ±15%; 2Parameter was varied from 50 to 90 kg; 3Parameter was varied according to lower and upper limit
values obtained from meta-analysis; 4Parameter was varied from 40 to 50 years old.
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presented in Table 6 for 24 weeks of treatment with
peginterferon-alfa-2a or peginterferon-alfa-2b, both in
association with a ribavirin.
In this setting, peginterferon-alfa-2a is a dominant
therapy compared to peginterferon-alfa-2b, i.e. less
costly ($Brz 4,345 savings) and more effective (0.10 LY
and 0.25 QALY gains).
Genotype 1
Overall cost for the treatment with peginterferon alfa-2a
was $Brz 31,185, while for peginterferon alfa-2b, total
cost was $Brz 39,186. Peginterferon-alfa-2a therapy
resulted in 14.51 LY and Clinical and economic result is
presented in Table 7 for 48 weeks of treatment with
peginterferon alfa-2a or peginterferon alfa-2b, both in
association with a ribavirin.Table 9 One-way sensitivity analysis results for genotype 1 co







Utility values1 -$Brz 8001 0,16
Medical costs1 -$Brz 7610 0,16







Patient weight2 -$Brz 2769 0,16
SVR3 -$Brz 7902 0,16
Starting age4 -$Brz 8181 0,20
Notes: 1Parameters were varied over the range of ±15%; 2Parameter was varied from
values obtained from meta-analysis; 4Parameter was varied from 40 to 50 years oldPeginterferon-alfa-2a is a dominant therapy also for
this genotype, with lower related costs ($Brz 8,001 sav-
ings) and higher effectiveness (0.16 LY and 0.39 QALY
gains).
Sensitivity analysis
By observing the results from the one-way sensitivity
analysis, in Tables 8 and 9, peginterferon-alfa-2a was a
dominant therapy in all scenarios: the drug yielded gains
in LYs and QALYs although incurred lower costs as op-
posed to peginterferon-alfa-2b. For genotype 2/3, vari-
ables with highest impact were patient weight, sustained
virological response and utility values. For genotype 1,
variables with highest impact were sustained patient
weight, utility values and peginterferon-alfa-2b acquisi-
tion cost.
Even considering a hypothetical scenario for genotype
2/3 with 50 kg patients, where peginterferon-alfa-2a costmparing peginterferon-alfa-2a to peginterferon-alfa-2b









0,54 -$Brz 8001 0,16 0,27 Dominant
0,41 -$Brz 8392 0,16 0,41 Dominant
0,37 -$Brz 8105 0,20 0,44 Dominant
0,41 -$Brz 6063 0,16 0,41 Dominant
0,41 -$Brz 10747 0,16 0,41 Dominant
0,41 -$Brz 13232 0,16 0,41 Dominant
0,39 -$Brz 8099 0,17 0,42 Dominant
0,45 -$Brz 7788 0,14 0,37 Dominant
50 to 90 kg; 3Parameter was varied according to lower and upper limit
.
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alfa-2b cost was simultaneously decreased by 15%,
peginterferon-alfa-2a would still be very cost-effective,
resulting in a low incremental cost-effectiveness ratio of
$Brz 894 per QALY.
Discussion
The results obtained from the meta-analysis are in line
with other six recently published meta-analyses (Awad,
2010 [8]; Alavian, 2010 [9]; Zhao, 2010 [10]; Xiao, 2010
[11]; Singal, 2011 [12] and Cheinquer, 2010 [13]) which
concluded that peginterferon-alfa-2a has a higher SVR
as compared to peginterferon-alfa-2b, with similar safety
profile.
This work applied a Markov model to represent the
treatment course of the disease, as well as to estimate the
cost-effectiveness ratio of the therapeutic schedule with
peginterferon-alfa-2a associated with ribavirin, when
compared to peginterferon-alfa-2b also associated with
ribavirin, aiming to evaluate which drug would represent
more advantages to the Brazilian public healthcare
system.
The model evaluated 2 different treatment regimens
according to patients genotype: patients diagnosed with
genotypes 2 and 3 would be eligible to receive 24 weeks
of treatment, while patients with genotype 1 would re-
ceive 48 weeks of treatment.
It is important to note that analysis presents limita-
tions regarding the usage of data from other countries to
adapt transition probabilities and evaluate quality of life.
The lack of Brazilian data should be supplied with more
studies on this field, which would enable more reliable
and accurate local economic analysis.
The extrapolation of results obtained in the analysis re-
vealed that therapy using peginterferon-alfa-2a presented
favorable results relative to health life years – LYs and
QALYs, being dominant compared to peginterferon-
alfa-2b, for a 24-week or 48-week treatment period.
Based on our results, the projections indicate that for
each 1000 patients treated with peginterferon-alfa-2a in-
stead of peginterferon-alfa-2b, the amount of resources
saved by the SUS can be of up to $Brz 4.3 million for ge-
notypes 2/3 and up to $Brz 8 million for genotype 1,
and that would allow the treatment of approximately
145 and 108 more patients, respectively.
Finally, it is important to stress that this study, which
enhances the available information on health economics
field in Brazil, intends to support medical and health-
care professionals, by providing adequate information in
decision-making on hepatitis C, a chronic disease which
requires special attention to be provided to patients and
to the management of resources used in its treatment.
Specially, with the introduction of new protease inhibitor
drugs, telaprevir and boceprevir, the triple therapy(association of telaprevir or boceprevir with pegylated
interferon and ribavirin) has been emerging as standard
of care for chronic hepatitis C. The introduction of those
new drugs significantly changes the landscape and costs
of HCV management. In this new scenario, multiple fac-
tors should be considered. Adoption of cost-effective
strategies would help decision makers to ensure appro-
priate usage of resources and proper treatment of
patients.
Conclusions
Our findings suggest that treatment with peginterferon-
alfa-2a is associated with higher clinical responses and out-
comes than peginterferon-alfa-2b. The pharmacoeconomic
analysis assessed peginterferon-alfa-2a as a dominant
therapy (more effective and less costly) as compared to
peginterferon-alfa-2b under SUS perspective in Brazil.
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